Stock Catalyst Radar helps investors and traders monitor public-market catalyst records in one focused research feed.
The app is designed to make public-source research faster by helping users track company, ticker, agency, sector, keyword, patent, filing, trial, and regulatory signals.
Stock Catalyst Radar currently references these public data sources:
SAM.gov: https://sam.gov
USAspending.gov: https://www.usaspending.gov
SEC EDGAR: https://www.sec.gov/edgar
USPTO: https://www.uspto.gov
ClinicalTrials.gov: https://clinicaltrials.gov
openFDA: https://open.fda.gov
Stock Catalyst Radar can help users monitor:
• Government contract and procurement-related records from SAM.gov and USAspending.gov
• SEC filing events from SEC EDGAR
• Patent-related information from USPTO
• FDA-related records from openFDA
• Clinical trial records from ClinicalTrials.gov
• Company, ticker, agency, and keyword matches
• Watchlists and alert rules with adjustable signal-score thresholds
Each signal is intended to help users review public information more efficiently. Where available, signals include source names, confidence labels, relevance scoring, and links to the original public record or source page.
SAM.gov live access can be expanded with a free SAM.gov API key. Users can create a SAM.gov account and generate an API key from Account Details in just a few minutes.
Important disclaimer:
Stock Catalyst Radar is not a government app. It is not affiliated with, endorsed by, sponsored by, or authorized by SAM.gov, USAspending.gov, the SEC, USPTO, FDA, ClinicalTrials.gov, openFDA, or any other government agency or public authority. The app does not represent any government entity.
Stock Catalyst Radar is an information and research tool only. It does not provide financial advice, investment advice, buy/sell/hold recommendations, brokerage services, portfolio management, or trade execution.
Source availability may depend on public data providers, network access, regional availability, and optional user-provided API credentials.
A Google Play subscription is required after the free trial period.
Track stock catalysts from gov contracts, patents, SEC, FDA and trials.